🇺🇸 FDA
Pipeline program

DIMETHYL FUMARATE, DIMETHYL FUMARATE

P170919

Phase 2 small_molecule active

Quick answer

DIMETHYL FUMARATE, DIMETHYL FUMARATE for Macular degeneration is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Macular degeneration
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials